Expanded Access Use of Human Umbilical Cord Blood (REGENECYTE) Infusion in Patients With Chronic Fatigue of Post-COVID Condition

Inclusion Criteria:

- Male or female aged ≥ 18

- With post-COVID condition

- Has had a recent (within 7 days) negative SARS-CoV-2 test (an approved PCR
(polyermerase chain reaction) or antigen test)

- Not eligible for participation in any ongoing clinical trials of post-COVID
condition with REGENECYTE

- Able to provide signed informed consent (by the subject or his/her legally
authorized representative)

- Is willing and able to participate in all aspects of the study, including completion
of subjective evaluations, attendance at scheduled clinic visits, and compliance
with all protocol requirements as evidenced by providing a written informed consent

Exclusion Criteria:

- Neurological disorders prior to COVID-19 diagnosis

- With pre-existing terminal illness

- With known immune disease

- Is pregnant or breastfeeding

- Is currently participating in another investigational study or has been taking any
other investigational product (IP) within the last 4 weeks before screening

- Has received any vaccination within 3 weeks prior to the first IP infusion or
planning to receive vaccination during the treatment period

- Judged by the investigator to be not suitable for study participation, including but
not limited to pre-existing chronic diseases

- Under the conditions that may increase risk of complications based on the medical
judgment of the investigator and the parameters